Favorable Response of Advanced Superior Sulcus Non-Small Cell Lung Carcinoma to Gefitinib for 11 years complicated by Interval Development of Small Cell Carcinoma of the Lung
Gefitinib is a medication that was originally developed as an epidermal growth factor receptor (EGFR) blocker. It has been used to treat non-small cell lung cancer with varying success. We describe a patient who presented with Pancoasts syndrome and after being deemed surgically unresectable had lim...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Marshall University
2018-01-01
|
| Series: | Marshall Journal of Medicine |
| Subjects: | |
| Online Access: | https://mds.marshall.edu/cgi/viewcontent.cgi?article=1158&context=mjm |